These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26986846)

  • 1. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
    Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F
    Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
    Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
    Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
    Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
    Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
    Sobhani M; Abdi J; Manujendra SN; Chen C; Chang H
    Cancer Biol Ther; 2015; 16(5):799-806. PubMed ID: 25803193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
    Tessoulin B; Descamps G; Moreau P; Maïga S; Lodé L; Godon C; Marionneau-Lambot S; Oullier T; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Blood; 2014 Sep; 124(10):1626-36. PubMed ID: 25006124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
    Li XL; Zhou J; Chan ZL; Chooi JY; Chen ZR; Chng WJ
    Oncotarget; 2015 Nov; 6(34):36689-99. PubMed ID: 26452133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
    Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
    Saha MN; Abdi J; Yang Y; Chang H
    Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Meher RK; Mir SA; Anisetti SS
    J Biomol Struct Dyn; 2024 May; 42(8):4169-4184. PubMed ID: 37272907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.
    Stuber G; Flaberg E; Petranyi G; Otvös R; Rökaeus N; Kashuba E; Wiman KG; Klein G; Szekely L
    Mol Cancer; 2009 Mar; 8():23. PubMed ID: 19323829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.
    Grellety T; Laroche-Clary A; Chaire V; Lagarde P; Chibon F; Neuville A; Italiano A
    BMC Cancer; 2015 Oct; 15():684. PubMed ID: 26463477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRIMA-1
    Mlakar V; Jurkovic Mlakar S; Lesne L; Marino D; Rathi KS; Maris JM; Ansari M; Gumy-Pause F
    J Exp Clin Cancer Res; 2019 Feb; 38(1):69. PubMed ID: 30755224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prima-1 and APR-246 in Cancer Therapy.
    Zatloukalová P; Galoczová M; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    Zache N; Lambert JM; Wiman KG; Bykov VJ
    Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
    Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
    Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
    Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
    Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.